TOMDF:OTCQB

Todos Medical

Todos Medical Inc. is a diversified diagnostics testing company that has engineered lifesaving diagnostic solutions for early detection of cancer and Alzheimer’s disease. Todos owns a CLIA/CAP certified lab called Provista Diagnostics. It generates significant revenue for the company and is currently being utilized to perform automated testing for institutional clients and growing very rapidly and has a capacity to do 20,000 PCR tests daily. Corona Diagnostics sells machines and PCR testing materials to automate testing labs. The company also has an oral antiviral treatment for hospitalized COVID-19 patients. The company also has developed a nutraceutical line of products for immune support and 3CL protease inhibition called Tollovid Maximum Strength and Tollovid Daily.
TOMDF:OTCQB
read more >
Vision and Value
read more >

Experts Following This Company


Company News 

1/27/2022 – Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir(TM) in the Treatment of Hospitalized COVID-19 Patients

1/24/2022 – Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients

1/18/2022 – Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies

1/12/2022 – Todos Medical to Announce Topline Results from Tollovir Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.

Investing Highlights
 
Major value inflection point of coming with interim clinical trial results EUA or Phase 3 IND
 
COVID Testing business booming and here to stay – Few automated labs have capacity
catalyst Calendar
Q1
2022
Precision Medicine Conference unveils interim phase 2 trial results – Jan 26
Q1
2022
Major marketing initiatives for Tollovid coming at Superbowl ad spend – Feb 14
Q1
2022
Completion of Crossover Round ($8.0 mill) and Debt elimination and NLC Acquisition completed
Todos Medical Content